All News
Filter News
Found 237 articles
-
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
5/2/2023
Tris Pharma, Inc. today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.
-
Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
5/2/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance across its global markets.
-
Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
4/26/2023
Mindset Pharma Inc. today announced that it has filed two international patent applications under the Patent Coorperation Treaty (“PCT”) for the protection of certain of Mindset’s non-hallucinogenic novel non-tryptamine compounds known as “Family 6.”
-
Vetter Performs Extraordinarily with Six Wins in the 12th Annual CDMO Leadership Awards
3/28/2023
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), earned the esteemed 2023 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service.
-
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
3/21/2023
AION Labs and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.
-
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
3/14/2023
Mindset Pharma Inc. today announced that the Company has been made aware that Reunion Neuroscience Inc. (“Reunion”) has filed a lawsuit against Mindset in the United States District Court for the District of New Jersey asserting, among others, inventorship and co-ownership of one of Mindset’s patents, inequitable conduct, and breach of contract.
-
AION Labs Launches AI Startup for De Novo Antibody Design
2/28/2023
AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of DenovAI, the lab's second startup approved by the Israel Innovation Authority.
-
As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.
-
Astellas Announces Change of President and CEO and Management Structure
2/6/2023
Astellas Pharma Inc. announced that at a meeting of its Board of Directors, held today, approved changes of its Representative Director, President and CEO and its management structure.
-
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
2/6/2023
PharmAla Biotech Holdings Inc. is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo MDMA and Engineering MDMA to Revive Therapeutics .
-
Mindset Pharma Announces Grant of Options
2/3/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that it has granted an aggregate of 6,065,000 options to purchase common shares of the Company
-
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
2/2/2023
Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset’s Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
-
AmerisourceBergen Announces Intent to Change Name to Cencora
1/24/2023
AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora.
-
Finding a mentor who can serve as a guide for one’s career is a goal for many young professionals. But reverse mentorship can be just as beneficial, as both parties stand to benefit.
-
Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates
1/20/2023
Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/833,341, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
-
Syneos Health Announces Partnership with Fosun Pharma USA to Launch SerplulimabRelationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions
1/11/2023
Syneos Health today announced a strategic partnership with Fosun Pharma USA Inc.
-
Pharnext Strengthens its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of Quality
1/4/2023
Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Scott Johnson as VP, Head of Quality.
-
Eliseo Salinas, M.D., head of R&D for Delix Therapeutics offers his perspective on what it takes to become a leader in the life sciences and how to begin that transition.
-
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
1/3/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced the appointment of Zachary J. Roberts M.D., Ph.D. to Executive Vice President of Research and Development.
-
Pfizer is rapidly scaling up its AI/ML efforts in a collaborative effort intended to get transformative medicines to patients faster.